GLP-1s linked to higher remission rates in ulcerative colitis

Clinical takeaway: When selecting diabetes or obesity treatment for patients with ulcerative colitis, consider the potential added benefit of a GLP-1 receptor agonist. Liraglutide or semaglutide use was associated with substantially higher symptomatic remission.

Ulcerative colitis can remain active despite advances in treatment, and some patients also require therapy for diabetes or obesity. New observational data suggest that choosing a GLP-1 receptor agonist for an established metabolic indication could potentially benefit both conditions.

Researchers matched 150 adults with ulcerative colitis who started liraglutide or semaglutide for metabolic indications with 150 adults not receiving a GLP-1 receptor agonist.

After 12 weeks, 66.7% of patients receiving GLP-1 therapy achieved symptomatic remission, defined by a low symptom score and no rectal bleeding, compared with 25.3% of controls. Improvement was evident within four weeks and increased over time.

Weight loss was not associated with remission, suggesting the findings may not simply reflect improved metabolic health. In the subset with follow-up endoscopy, GLP-1 therapy was also associated with higher rates of endoscopic remission and improvement, supporting a possible effect on inflammatory disease activity.

Semaglutide was associated with somewhat higher remission rates than liraglutide, but the observational comparison is not sufficient to guide selection between the drugs.

The results add a potentially relevant consideration when choosing metabolic therapy for patients with ulcerative colitis. Prospective trials are needed before GLP-1 receptor agonists can be considered treatments for ulcerative colitis or used in place of established therapies.

“These findings support a potential adjunctive role for GLP-1 RAs in UC, particularly in patients with metabolic comorbidities,” the study authors concluded.

Source: Alqinai B, et al. (2026 Aug 21) Inflamm Bowel Dis. GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study